Here are relevant reports on : oat-beta-glucan-market
-
Carotenoids Market by Type (Astaxanthin, Beta-Carotene, Lutein, Lycopene, Canthaxanthin, Zeaxanthin), Application (Food & Beverage, Feed, Pharmaceuticals, Dietary Supplements, Cosmetics), Form, Nature, Function, and By Region - Global Forecast to 2031
The carotenoids market is estimated to be USD 2.58 billion in 2026 and is projected to reach USD 3.52 billion by 2031, at a CAGR of 6.4% from 2026 to 2031. The report profiles key players such as BASF SE (Germany), dsm-firmenich (Netherlands), Cyanotech Corporation (US), Givaudan (Switzerland), Zhejiang NHU Co., Ltd. (China), Divi's Laboratories Limited (India), Lycored (US), Allied Biotech Corporation (Taiwan), Kemin Industries, Inc. (US), EW Nutrition (Germany), Döhler GmbH (Germany), Solabia Group (France), Ambe Phytoextracts Pvt. Ltd. (India), Fuji Chemical Industries Co., Ltd. (Japan), and Bio-gen Extracts Pvt. Ltd. (India), among others.
- Published: August 2026
- Price: $ 4950
- TOC Available:
-
Crude Sulfate Turpentine Market by Type (Alpha Pinene, Beta Pinene, Delta 3 Carene, Camphene, Limonene), Application (Aromatic Chemicals, Adhesives, Paints and printing inks, Camphor), and Region - Global Forecast to 2022
The crude sulfate turpentine market is projected to grow at a CAGR of 4.10% from 2016 to 2022, to reach a projected value of USD 279.5 Million by 2022. Crude sulfate turpentine has become prominent in recent years due to the increasing demand for fragrance ingredients that require crude sulfate turpentine derivatives; increasing preference of consumers towards eco-friendly products that include crude sulfate turpentine as a substitute to petrochemicals; and increasing demand for personal care products such as perfumes, detergents, and soaps.
- Published: November 2016
- Price: $ 4950
- TOC Available:
-
European Nuclear Medicine/Radiopharmaceuticals Market by Type (Diagnostic (SPECT - Technetium, PET - F-18), Therapeutic (Beta Emitters - I-131, Alpha Emitters, Brachytherapy - Y-90)), Application (Oncology, Thyroid, Cardiology), Procedures - Forecasts to 2020
Over the years, the European nuclear medicine/radiopharmaceuticals market has witnessed various advancements in radiopharmaceuticals. The European radiopharmaceuticals market is witnessing growth owing to an increasing number of radioisotope approvals for different clinical indications. Tc-99m and F-18 radioisotopes are estimated to contribute the highest to the European nuclear medicine diagnostic market in 2015, whereas Ra-223, I-131 and Y-90 ensured their leading position in the therapeutic market. The European nuclear medicine/radiopharmaceuticals market is expected to reach $1.62 Billion by 2020 from $1.09 Billion in 2015, growing at a CAGR of 8.2% from 2015 to 2020.
- Published: November 2015
- Price: $ 4950
- TOC Available:
-
Phytosterols Market by Composition (Beta-Sitosterol, Campesterol, Stigmasterol), Application (Food & Beverages, Pharmaceutical, Cosmetics & Personal Care Products, and Feed), Form( Dry, Liquid), Source and Region - Global Forecast to 2028
According to MarketsandMarkets, the phytosterol market is projected to reach USD 1.6 billion by 2028, at a CAGR of 8.3% during the forecast period in terms of value. The key players in this market include ADM (US), BASF SE (Germany), Cargill, Incorporated (US), International Flavors & Fragrances Inc. (US), Ashland (US)Matrix Life Science (India), AOM (Argentina), Lipofoods (Spain), Avanti Polar Lipids (US), DRT (France), Wilmar International Ltd (Singapore), VITAE NATURALS (Spain), TAMA BIOCHEMICALS CO., LTD (Japan), BOC Sciences (US), Herbo Nutra (India). The study includes an in-depth competitive analysis of these key players in the phytosterol market with their company profiles, recent developments, and key market strategies.
- Published: May 2023
- Price: $ 4950
- TOC Available:
-
Brewing Enzymes Market by Type (Amylase, Beta-glucanase, Protease, Xylanase, ALDC, Pectinase), Application (Beer and Wine), Source (Microbial and Plant), Form (Liquid and Powder), Process, and Region - Global Forecast to 2023
The brewing enzymes market is estimated at USD 352.1 million in 2018. It is projected to reach USD 484.7 million by 2023, at a CAGR of 6.6% from 2018, in terms of value. The use of enzymes has become increasingly important in the brewing industry, as they accelerate the chemical reaction without a change in their own structure. To enhance the brewing process, commercial exogenous enzymes are used in various steps to make the brewing faster, easier, and more consistent. The demand for brewing enzymes in the beer segment is expected to witness significant growth in the near future, due to the rising popularity of beer consumption among young consumers, rise in technological innovations, and growth in the craft beer segment and number of microbreweries. This report studies the marketing and development strategies, along with the product portfolios of leading companies such as Novozymes (Denmark), DSM (Netherlands), DowDuPont (US), Amano Enzyme (Japan), Chr. Hansen (Denmark), Associated British Foods (UK), Kerry Group (Ireland), Brenntag (Germany), Enzyme Development Corporation (US), Aumgene Biosciences (India), Biocatalysts (UK), and Enzyme Innovation (US).
- Published: July 2018
- Price: $ 4950
- TOC Available:
-
Asia-Pacific Nuclear Medicine/Radiopharmaceuticals & Stable Isotopes Market [SPECT/PET Radioisotopes (Technetium, F-18)], [Beta/Alpha Radiation Therapy (I131, Y-90)], [Applications (Cancer/Oncology, Cardiac)] & (Deuterium, C-13) – Forecast to 2017
The market is broadly classified into two segments, namely, diagnostic and therapeutic; the former dominated with about 80.7% share in 2012. Radioisotopes in the diagnostic market are categorized as SPECT and PET. Technetium 99m (Tc-99m) dominated the SPECT radioisotope market in 2012, followed by thallium–201(Tl-201), gallium–67 (Ga-67), and iodine-123 (I-123). SPECT is majorly used in cardiology-related diagnosis; it is poised to grow at a CAGR of 10.2% from 2012 to 2017. The radiopharmaceuticals market in the Asia-Pacific region was valued at $500.8 million in 2012; it is poised to reach $824.9million in 2017 at a CAGR of 10.5%.
- Published: May 2013
- Price: $ 4950
- TOC Available:
-
Soluble Fibre Ingrdient Market By Type (Inulin, Corn Fibres, Polydextrose, Resistant Starch, Beta-Glucan, Other) By Function (Cancer, Diabetes, Gastrointestinal, Health, Heart Disease, Immune Health, Prebiotics, Weight Management) By Geography (NA,Europe,APAC,ROW)
- Published: December 2026
- Price: $ 4950
- TOC Available:
-
Soluble Fibre Ingrdient Market, By Type (Inulin, Corn Fibres, Polydextrose, Resistant Starch, Beta-Glucan, Other) By Function (Cancer, Diabetes, Gastrointestinal , Health, Heart Disease, Immune Health, Prebiotics, Weight Management) By Geography (NA, Europe, APAC, ROW)
- Published: December 2026
- Price: $ 4950
- TOC Available:
-
Europe Nuclear Medicine Market by Type (SPECT [Tc99m, I-123], PET [F-18, Rb-82], Alpha Emitters, Beta Emitters [Y-90, I-131], Brachytherapy), Application (Onco, Cardio), Procedure, End User (Imaging Center, Hospital) - Forecast to 2030
The Europe nuclear medicine market, valued at USD 2.14 billion in 2024, stood at USD 2.47 billion in 2025 and is projected to advance at a resilient CAGR of 15.8% from 2025 to 2030, culminating in a forecasted valuation of USD 5.15 billion by the end of the period. This growth is driven by the rising application of radiopharmaceuticals and radioisotopes for diagnostic imaging and targeted radionuclide therapies, especially in oncology, cardiology, and neurology. The major drivers of the demand include rising cancer incidence, the aging population, and the high adoption of the PET and SPECT procedures in key European nations.
- Published: November 2026
- Price: $ 4950
- TOC Available:
-
US Nuclear Medicine Market by Type (SPECT [Tc99m, I-123, Ga-67], PET [F-18], Alpha Emitters, Beta Emitters [Y-90, Lu-177]), Application (Onco, Neuro), Procedure, End User (Imaging Center, Hospital), Radioisotope, Market Share, Growth - Forecast to 2030
The US Nuclear Medicine market, valued at USD 4.19 billion in 2024, stood at USD 4.81 billion in 2025 and is projected to advance at a resilient CAGR of 14.7% from 2025 to 2030, culminating in a forecasted valuation of USD 9.56 billion by the end of the period. This growth is attributed to the rapid expansion of theranostics and radioligand therapies, growing FDA approval of novel radiopharmaceuticals, and active clinical research at the US hospitals and academic medical centers.
- Published: November 2026
- Price: $ 4950
- TOC Available:
Records 11 to 20 of 50
